ParagonDx Expected to Genotype over Two Thousand People for Warfarin Sensitivity at AACC Annual Conference
7/21/2008 12:30:38 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--ParagonDx, LLC, a leader in genetic testing diagnostics, will lead a group of five organizations in an unprecedented display of personalized medicine diagnostics. Thousands of attendees at the annual meeting of the American Association of Clinical Chemistry (AACC) will have the opportunity to take a genetic test that helps determine an individual’s sensitivity to warfarin (also known as Coumadin®), a blood thinner that prevents and treats blood clots. The test will be conducted entirely on the floor of the convention, with results delivered in just a few hours. ParagonDx expects to collect over 2,000 samples for testing during the four-day conference that will run from July 28-31 in Washington, D.C.
comments powered by